Table 1. Demographics of the patient cohorts.
| EAC cohorts | Barrett’s esophagus cohorts | TP53 analysis on Cytosponge™ | ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Discovery | Validation | Never-dysplastic Barrett’s esophagus |
Barrett’s esophagus with HGD |
No Barrett’s esophagus Controls |
Never-dysplastic Barrett’s esophagus |
Barrett’s esophagus with HGD |
||
| Number | 22 | 90 | 40 | 39 | 23 | 44 | 22 | |
|
| ||||||||
| Age (years) | 68 (53-82) | 66 (32-83) | 63 (32-81) | 71 (50-87) | 53 (28-74) | 61 (41-85) | 66 (41-82) | |
|
| ||||||||
| Sex (M:F) | 5:1 | 5 : 1 | 2 : 1 | 12:1 | 1 : 2 | 4 : 1 | 10 : 1 | |
|
| ||||||||
| Stage (%) | I | 4 (18.2) | 14 (15.6) | |||||
| II | 6 (27.3) | 14 (15.6) | ||||||
| III | 11 (50.0) | 49 (54.4) | ||||||
| IV | 1 (4.5) | 4 (4.4) | ||||||
| n/a | 0 (0.0) | 9(10.0) | ||||||
|
| ||||||||
| Barrett’s esophagus length (cm) | 4.8 (1-9) | 8.6 (2-16) | 5.8 (1-12) | 8.5 (4-16) | ||||
|
| ||||||||
| Follow up from EAC diagnosis (months) | 28.5 (5-63) | 18 (1-134) | ||||||
|
| ||||||||
| Total Barrett’s esophagus surveillance (months) | 58 (4-132) | 1 (0-45) | 56 (0-175) | 24 (0-180) | ||||
*
Data shown reflect mean (range) for age and Barrett’s esophagus length, number (percentage) for stage and median (range) for follow up from EAC diagnosis and total Barrett’s esophagus surveillance. Sex ratio rounded to the nearest whole number.